Abstract: The present invention disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the invention is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The invention includes two target-specific nucleic acid probes per genetic target, a barcode loop oligo and a bridge oligo or bridge oligo complex.
Type:
Application
Filed:
March 21, 2024
Publication date:
August 1, 2024
Applicant:
Genomill Health Oy
Inventors:
Juha-Pekka Pursiheimo, Tatu Hirvonen, Anttoni Korkiakoski, Manu Tamminen
Abstract: The present disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the disclosed embodiments is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The disclosed embodiments includes two target-specific nucleic acid probes per genetic target, a barcode loop oligo and a bridge oligo or bridge oligo complex.
Type:
Grant
Filed:
August 31, 2022
Date of Patent:
April 30, 2024
Assignee:
Genomill Health Oy
Inventors:
Juha-Pekka Pursiheimo, Tatu Hirvonen, Anttoni Korkiakoski, Manu Tamminen
Abstract: The present invention disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the invention is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The invention includes two target-specific nucleic acid probes per genetic target, a barcode loop oligo and a bridge oligo or bridge oligo complex.
Type:
Application
Filed:
August 31, 2022
Publication date:
February 29, 2024
Applicant:
Genomill Health Oy
Inventors:
Juha-Pekka Pursiheimo, Tatu Hirvonen, Anttoni Korkiakoski, Manu Tamminen
Abstract: The present invention disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the invention is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The invention includes at least target-specific nucleic acid probes per genetic target (first probe, second probe and target-specific probe) and a bridge oligo or bridge oligo complex.
Type:
Application
Filed:
August 31, 2022
Publication date:
February 29, 2024
Applicant:
Genomill Health Oy
Inventors:
Juha-Pekka Pursiheimo, Tatu Hirvonen, Anttoni Korkiakoski, Manu Tamminen
Abstract: The present invention disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the invention is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The invention includes one or more target-specific nucleic acid probes per genetic target and a bridge oligo or bridge oligo complex.
Type:
Grant
Filed:
March 3, 2022
Date of Patent:
February 13, 2024
Assignee:
Genomill Health Oy
Inventors:
Juha-Pekka Pursiheimo, Tatu Hirvonen, Manu Tamminen, Anttoni Korkiakoski
Abstract: The present disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the present disclosure is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The disclosed embodiments includes one or more target-specific nucleic acid probes per genetic target (left probe and right probe) and a bridge oligo or bridge oligo complex.
Type:
Grant
Filed:
March 3, 2022
Date of Patent:
November 1, 2022
Assignee:
Genomill Health Oy
Inventors:
Juha-Pekka Pursiheimo, Tatu Hirvonen, Manu Tamminen, Anttoni Korkiakoski
Abstract: The present disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the present disclosure is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The disclosed embodiments includes one or more target-specific nucleic acid probes per genetic target (left probe and right probe) and a bridge oligo or bridge oligo complex.
Type:
Application
Filed:
March 3, 2022
Publication date:
September 22, 2022
Applicant:
Genomill Health Oy
Inventors:
Juha-Pekka Pursiheimo, Tatu Hirvonen, Manu Tamminen, Anttoni Korkiakoski
Abstract: The present invention disclosure relates to a next generation DNA sequencing method and use for accurate and massively parallel quantification of one or more nucleic acid targets, for example in large volumes of unpurified sample material. More particularly, the invention is related to a method and a kit comprising probes for detecting and quantifying genetic targets in complex samples. The invention includes one or more target-specific nucleic acid probes per genetic target and a bridge oligo or bridge oligo complex.
Type:
Application
Filed:
March 3, 2022
Publication date:
September 22, 2022
Applicant:
Genomill Health Oy
Inventors:
Juha-Pekka Pursiheimo, Tatu Hirvonen, Manu Tamminen, Anttoni Korkiakoski